Efficacy and safety of universal (TCRKO) ARI-0001 CAR-T cells for the treatment of B-cell lymphoma

Autologous T cells expressing the Chimeric Antigen Receptor (CAR) have been approved as advanced therapy medicinal products (ATMPs) against several hematological malignancies. However, the generation of patient-specific CAR-T products delays treatment and precludes standardization. Allogeneic off-th...

Descripción completa

Detalles Bibliográficos
Autores principales: Maldonado-Pérez, Noelia, Tristán-Manzano, María, Justicia-Lirio, Pedro, Martínez-Planes, Elena, Muñoz, Pilar, Pavlovic, Kristina, Cortijo-Gutiérrez, Marina, Blanco-Benítez, Carlos, Castella, María, Juan, Manel, Wenes, Mathias, Romero, Pedro, Molina-Estévez, Francisco J., Marañón, Concepción, Herrera, Concha, Benabdellah, Karim, Martin, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585383/
https://www.ncbi.nlm.nih.gov/pubmed/36275777
http://dx.doi.org/10.3389/fimmu.2022.1011858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9585383/
https://www.ncbi.nlm.nih.gov/pubmed/36275777
http://dx.doi.org/10.3389/fimmu.2022.1011858

Ejemplares similares